{"id":93374,"date":"2023-12-18T00:41:04","date_gmt":"2023-12-17T19:11:04","guid":{"rendered":"http:\/\/finservwealth.com\/bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papers-with-reduced-issue-size\/"},"modified":"2023-12-18T00:41:04","modified_gmt":"2023-12-17T19:11:04","slug":"bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papers-with-reduced-issue-size","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papers-with-reduced-issue-size\/","title":{"rendered":"Bain Capital-backed Emcure Pharmaceuticals refiles IPO papers with reduced issue size"},"content":{"rendered":"<p> Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan.<\/p><div id=\"finse-1390934465\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papersreduced-issue-size_17372481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan. Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papersreduced-issue-size_17372481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papersreduced-issue-size_17372481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan. Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/ipo-news\/bain-capital-backed-emcure-pharmaceuticals-refiles-ipo-papersreduced-issue-size_17372481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Emcure Pharmaceuticals IPO | The IPO is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.37 crore equity shares by the existing shareholders, which both are lower in size compared to previous fund raising plan.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-93374","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/p\/pharma_tablet_injection_capsule_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/93374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=93374"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/93374\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=93374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=93374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=93374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}